Showing results (101-110 of 117) with videos related to
Sort By:
Pageof 12
Scientific Reports|December 23, 2015
Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Santini Daniele, Sandro Barni, et al.Communications Biology|February 27, 2020
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigensAlessio Grimaldi, Ilenia Cammarata, Carmela Martire, et al.Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.Urologic Oncology|April 25, 2015
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and youngerOrazio Caffo, Cinzia Ortega, Giuseppe Di Lorenzo, et al.Future Oncology (London, England)|January 19, 2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancerAntonello Veccia, Orazio Caffo, Ugo De Giorgi, et al.Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.Pageof 12